Suzanne Kyle
Impact in
- Oncology top 0.2%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- Molecular Biology top 1%
- DNA Repair Mechanisms
- CRISPR and Genetic Engineering
- Cancer therapeutics and mechanisms
- Cell death mechanisms and regulation
Papers in
- Oncology 20
- PARP inhibition in cancer therapy 18
- Cancer-related Molecular Pathways 2
-
- DNA Repair Mechanisms 12
- Cancer therapeutics and mechanisms 6
- CRISPR and Genetic Engineering 2
- Co-authors
- Nicola J. Curtin (19 shared papers)Huw D. Thomas (12 shared papers)Thomas Helleday (3 shared papers)Mark Meuth (2 shared papers)Elena López‐Knowles (2 shared papers)Niklas Schultz (2 shared papers)Helen E. Bryant (2 shared papers)Zdeněk Hostomský (10 shared papers)
- Journals
- Clinical Cancer Research (4 papers)British Journal of Cancer (4 papers)Molecular Cancer Therapeutics (3 papers)Nature (2 papers)Cancer Research (2 papers)
- Partner nations
- United KingdomUnited StatesSweden
In The Last Decade
Suzanne Kyle
23 papers receiving 5.6k citations
Suzanne Kyle's Hit Papers
Peers
Comparison fields: 5 of 99
- Oncology 4.0k
- Molecular Biology 3.8k
- Reproductive Medicine 331
- Cancer Research 556
- Genetics 678
Countries citing papers authored by Suzanne Kyle
This map shows the geographic impact of Suzanne Kyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Kyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Kyle more than expected).
Fields of papers citing papers by Suzanne Kyle
This network shows the impact of papers produced by Suzanne Kyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Kyle. The network helps show where Suzanne Kyle may publish in the future.
Co-authors
The 25 scholars most cited alongside Suzanne Kyle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Hit paper breakdown → | 2005 | 3823 |
| 2 | 2007 | 235 | |
| 3 | 2010 | 211 | |
| 4 | 2010 | 192 | |
| 5 | Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. | 2000 | 164 |
| 6 | 2011 | 153 | |
| 7 | 2004 | 120 | |
| 8 | 2013 | 114 | |
| 9 | 1996 | 109 | |
| 10 | 2010 | 80 | |
| 11 | Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. | 2003 | 64 |
| 12 | 2012 | 60 | |
| 13 | 2004 | 59 | |
| 14 | 2011 | 44 | |
| 15 | 2009 | 42 | |
| 16 | 2007 | 37 | |
| 17 | 2014 | 33 | |
| 18 | 2004 | 33 | |
| 19 | 2008 | 30 | |
| 20 | 2000 | 27 |
About Suzanne Kyle
Suzanne Kyle is a scholar working on Oncology, Molecular Biology, Immunology, Genetics and Cardiology and Cardiovascular Medicine, having authored 25 papers that have together received 5.7k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (18 papers), DNA Repair Mechanisms (12 papers), Cancer therapeutics and mechanisms (6 papers), Toxin Mechanisms and Immunotoxins (3 papers), BRCA gene mutations in cancer (2 papers), Cancer-related Molecular Pathways (2 papers), CRISPR and Genetic Engineering (2 papers) and VLSI and Analog Circuit Testing (1 paper). The work is most often cited by research in Oncology (4.0k citations), Molecular Biology (3.8k citations), Reproductive Medicine (331 citations), Cancer Research (556 citations) and Genetics (678 citations). Suzanne Kyle has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Nicola J. Curtin, Huw D. Thomas, Thomas Helleday, Mark Meuth, Elena López‐Knowles, Niklas Schultz, Helen E. Bryant, Zdeněk Hostomský, David R. Newell and Barbara W. Durkacz. Their work appears in journals such as Clinical Cancer Research, British Journal of Cancer, Molecular Cancer Therapeutics, Nature and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.